Most read article(s)

Article
COVID-19 and MS disease-modifying therapies
Joseph R. Berger, Rachel Brandstadter, Amit Bar-Or

May 15, 2020
Article
Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome
Jonathan D. Santoro, Lauren M. Kerr, Rachel Codden, et al.

September 02, 2021
Article
CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
Manuel Comabella, Jaume Sastre-Garriga, Eva Borras, et al.

September 08, 2021
Article
Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple SclerosisA Randomized, Controlled Trial
Helene Højsgaard Chow, Jacob Talbot, Henrik Lundell, et al.

August 24, 2021
Article
SARS-CoV-2 Infection in Multiple SclerosisResults of the Spanish Neurology Society Registry
Georgina Arrambide, Miguel Ángel Llaneza-González, Lucienne Costa-Frossard França, et al.

June 24, 2021
Clinical/Scientific Notes
Guillain-Barré syndrome related to COVID-19 infection
Paola Alberti, Simone Beretta, Marco Piatti, et al.

April 29, 2020
Article
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.

July 14, 2021
Views & Reviews
Autoimmune NeurologyThe Need for Comprehensive Care
Justin R. Abbatemarco, Stefanie J. Rodenbeck, Gregory S. Day, et al.

June 15, 2021
Clinical/Scientific Notes
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
Alberto Picca, Nefeli Valyraki, Cristina Birzu, et al.

September 08, 2021
Article
Targeted RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Temporal Arteries From Giant Cell Arteritis Cases Reveals Viral Signatures
Andrew N. Bubak, Teresa Mescher, Michael Mariani, et al.

September 07, 2021

Pages